In the last 12 days of July, 89,261 young people in England walked into a pharmacy and walked out with a first dose of the meningitis B vaccine [1]. That figure comes from NHS England, which ran the count from 20 to 31 July 2026 and calls this the first campaign of its kind: a catch-up drive delivered not through GP surgeries or schools but through the local chemist.
More than 8,200 pharmacies signed up to give the shot [1]. Week one alone, from 20 to 27 July, logged over 135,000 bookings [1]. The appeal of the model is its reach into ordinary routines. A pharmacy sits on a high street, stays open into the evening, and does not require an appointment weeks out, which is why tens of thousands of doses landed in a fortnight rather than a season.
The campaign exists because of a scare. In March 2026, a meningitis outbreak hit students and young people in Kent [1]. Meningitis B is the reason that kind of news travels fast among parents: it can move from first symptoms to critical illness within hours, and survivors can be left with amputations, hearing loss, or brain injury. A vaccine gap in the age group most exposed is not an abstraction, and the Kent cases made that plain.
Roughly one million young people are eligible for the catch-up [1]. The offer covers those born on or after 1 September 2007 through 31 August 2008, along with anyone born on or after 21 July 2001 who is starting university or residential further education this autumn [1]. That second group matters because meningitis spreads readily in the close quarters of halls of residence, where a new cohort arrives every September.
Caroline Temmink, an NHS director, framed the opening numbers plainly. "This first of its kind vaccination programme has made a great start, with tens of thousands of young people given the first step towards vital protection in just under a fortnight" [1].
Her phrase, first step, is doing real work. Full protection against MenB takes two doses given a minimum of 28 days apart [1]. The 89,261 recorded so far are the people who have started, not the people who have finished, and the gap between the two is where a fast start can still fade. More than 900,000 eligible young people have not yet had a first dose at all.
What the fortnight proves is narrower and more useful than a victory lap. When an outbreak exposes a hole in coverage, a delivery channel that meets people where they already are can close a large part of it quickly. The pharmacies did in two weeks what a slower rollout might have stretched across months. The number to watch now is not the first dose but the second.
